GlassScriptPhysician profile
Marta Roman
NPI 1114579992
$2,889.71
in general payments reported to CMS, 2019-2025
11 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $75.80 · 2022: $810 · 2023: $119 · 2024: $261 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Travel and Lodging: $751 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.35 |
| Travel and Lodging | $750.69 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,307.22 | 2020-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,155.68 | 2024-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $71.59 | 2025 | Xdemvy |
| Harrow Eye, LLC | $71.33 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $52.17 | 2025 | |
| Dompe US, INC. | $50.79 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $48.41 | 2024-2025 | |
| Oyster Point Pharma, INC. | $47.59 | 2024-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $40.84 | 2024-2025 | Eysuvis |
| Abbvie INC. | $25.33 | 2025 | |
| Abb Con-Cise Optical Group LLC | $18.76 | 2024 | Contact Lens, Spectacle Lenses |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.